Pimecrolimus reduces eosinophil activation associated with calcium mobilization.

about

Staphylococcus aureus directly activates eosinophils via platelet-activating factor receptor.

P2860

Q34272784-61470610-0B7F-4BA1-86DB-7396647157E6

P2860

Pimecrolimus reduces eosinophil activation associated with calcium mobilization.

Item

http://www.wikidata.org/entity/Q42643465

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

2009年论文

@zh

2009年论文

@zh-cn

name

Pimecrolimus reduces eosinophil activation associated with calcium mobilization.

@en

Pimecrolimus reduces eosinophil activation associated with calcium mobilization.

@nl

type

Item

label

Pimecrolimus reduces eosinophil activation associated with calcium mobilization.

@en

Pimecrolimus reduces eosinophil activation associated with calcium mobilization.

@nl

prefLabel

Pimecrolimus reduces eosinophil activation associated with calcium mobilization.

@en

Pimecrolimus reduces eosinophil activation associated with calcium mobilization.

@nl

P1476

Pimecrolimus reduces eosinophil activation associated with calcium mobilization.

@en

P2093

Arvind Madaan

http://www.w3.org/2001/XMLSchema#string

Diane L Squillace

http://www.w3.org/2001/XMLSchema#string

Douglas A Plager

http://www.w3.org/2001/XMLSchema#string

Hirohito Kita

http://www.w3.org/2001/XMLSchema#string

Ross A Dierkhising

http://www.w3.org/2001/XMLSchema#string

Susan A Henke

http://www.w3.org/2001/XMLSchema#string

Yoshinori Matsuwaki

http://www.w3.org/2001/XMLSchema#string

P2860

Pharmacology of the eosinophil

A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology

Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee

Use of specific IgE in assessing the relevance of fungal and dust mite allergens to atopic dermatitis: a comparison with asthmatic and nonasthmatic control subjects.

Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis.

Eosinophils and atopic dermatitis.

The burden of atopic dermatitis: impact on the patient, family, and society.

Exposure to Alternaria alternata in US homes is associated with asthma symptoms

Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis.

Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report.

P304

119-126

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000189194

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

149

http://www.w3.org/2001/XMLSchema#string

P577

2009-01-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23762053

http://www.w3.org/2001/XMLSchema#string

P698

19127068

http://www.w3.org/2001/XMLSchema#string

P932

2718564

http://www.w3.org/2001/XMLSchema#string

Pimecrolimus reduces eosinophil activation associated with calcium mobilization.

about

P2860

P2860

Pimecrolimus reduces eosinophil activation associated with calcium mobilization.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932